CANF Key Statistics, Chart & Performance
The current stock price of CANF is 4.16 USD. In the past month the price decreased by -31.23%. In the past year, price decreased by -86.2%.
CANF Latest News, Press Relases and Analysis
CANF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.33 | 389.70B | ||
| AMGN | AMGEN INC | 15.03 | 177.04B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 149.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.19 | 119.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.84 | 84.39B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 797.17 | 53.71B | ||
| INSM | INSMED INC | N/A | 37.49B | ||
| NTRA | NATERA INC | N/A | 32.36B | ||
| BIIB | BIOGEN INC | 11.18 | 27.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.39 | 20.89B | ||
| INCY | INCYTE CORP | 16.52 | 20.82B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 21.85B |
Related stock screener links
About CANF
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
CAN FITE BIOPHARMA LTD-ADR
10 Bareket Street, Kiryat Matalon, P.O. Box 7537
Petah Tikva 4951778 IL
CEO: Pnina Fishman
Employees: 5
Phone: 97239241114
CAN FITE BIOPHARMA LTD-ADR / CANF FAQ
Can you describe the business of CAN FITE BIOPHARMA LTD-ADR?
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
What is the stock price of CAN FITE BIOPHARMA LTD-ADR today?
The current stock price of CANF is 4.16 USD. The price decreased by -4.59% in the last trading session.
What is the dividend status of CAN FITE BIOPHARMA LTD-ADR?
CANF does not pay a dividend.
How is the ChartMill rating for CAN FITE BIOPHARMA LTD-ADR?
CANF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of CANF stock?
CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 71.02M USD. This makes CANF a Micro Cap stock.
What is the Short Interest ratio of CAN FITE BIOPHARMA LTD-ADR (CANF) stock?
The outstanding short interest for CAN FITE BIOPHARMA LTD-ADR (CANF) is 0.19% of its float.
CANF Technical Analysis
CANF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CANF. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability.
CANF Financial Highlights
Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 40% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -102.07% | ||
| ROE | -188.34% | ||
| Debt/Equity | 0 |